Role of blood-brain barrier P-glycoprotein in limiting brain accumulation and sedative side-effects of asimadoline, a peripherally acting analgaesic drug

British Journal of Pharmacology

Volumn 127, Issue 1, 1999, Pages 43-50

  Jonker, J W ^a   Wagenaar, E ^a   Van Deemter, L ^b   Gottschlich, R ^c   Bender, H M ^c   Dasenbrock, J ^c   Schinkel, A H ^a  

^a NETHERLANDS CANCER INSTITUTE   (Netherlands)

^b Division of Tumor Biology   (Netherlands)

^c MERCK KGAA   (Germany)

Author keywords

opioid receptor agonist; Asimadoline (EMD 61753); Blood brain barrier; Drug disposition; Oral availability; P glycoprotein

Indexed keywords

ANALGESIC AGENT; ASIMADOLINE; GLYCOPROTEIN P;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BLOOD BRAIN BARRIER; CONTROLLED STUDY; DNA TRANSFECTION; DRUG ACCUMULATION; DRUG BRAIN LEVEL; DRUG TRANSPORT; KIDNEY EPITHELIUM; KNOCKOUT MOUSE; MALE; MOUSE; MULTIDRUG RESISTANCE; NONHUMAN; PRIORITY JOURNAL; SEDATION; SWINE;

ACETAMIDES; ANALGESICS, OPIOID; ANIMALS; ATP-BINDING CASSETTE TRANSPORTERS; BIOLOGICAL AVAILABILITY; BLOOD-BRAIN BARRIER; BRAIN; CELL LINE; HUMANS; MALE; MICE; MICE, KNOCKOUT; P-GLYCOPROTEIN; P-GLYCOPROTEINS; PYRROLIDINES; SLEEP STAGES; SWINE; TISSUE DISTRIBUTION;

EID: 0032960014     PISSN: 00071188     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjp.0702497     Document Type: Article

References (27)

1. Barber, A., Bartoszyk, G.D., Bender, H.M., Gottschlich, R., Greiner, H.E., Harting, J., Mauler, F., Minck, K.O., Murray, R.D., Simon, M. & Seyfried, C.A. (1994). A pharmacological profile of the novel, peripherally-selective kappa-opioid receptor agonist, EMD 61753. Br. J. Pharmacol., 113, 1317-1327.
2. Borst, P. & Schinkel, A.H. (1997). Genetic dissection of the function of mammalian P-glycoproteins. Trends Genet., 13, 217-222.
3. Chen, C., Chin, J.E., Ueda, K., Clark, D.P., Pastan, I., Gottesman, M.M. & Roninson, I.B. (1986). Internal duplication and homology with bacterial transport proteins in the mdr 1 (P-glycoprotein) gene from multidrug-resistant human cells. Cell, 47, 381-389.
4. Cordon-Cardo, C., O'Brien, J.P., Casals, D., Rittmangrauer, L., Biedler, J.L., Melamed, M.R. & Bertino, J.R. (1989). Multidrug resistance gene (P-glycoprotein) is expressed by endothelial cells at blood-brain barrier sites. Proc. Natl. Acad. Sci. U.S.A., 86, 695-698.
5. Drion, N., Lemaire, M., Lefauconnier, J.M. & Scherrmann, J.M. (1996). Role of P-glycoprotein in the blood-brain transport of colchicine and vinblastine. J. Neurochem., 67, 1688-1693.
6. Endicott, J.A. & Ling, V. (1989). The biochemistry of P-glycoprotein-mediated multidrug resistance. Annu. Rev. Biochem., 58, 137-171.
7. Fricker, G., Drewe, J., Huwyler, J., Gutmann, H. & Beglinger, C. (1996). Relevance of p-glycoprotein for the enteral absorption of cyclosporin A: in vitro-in vivo correlation. Br. J. Pharmacol., 118, 1841-1847.
8. Gottesman, M.M. & Pastan, I. (1993). Biochemistry of multidrug resistance mediated by the multidrug transporter. Anna. Rev. Biochem., 62, 385-427.
9. Gottschlich, R., Barber, A., Bartoszyk, G.D. & Seyfried, C.A. (1995). The peripherally acting Κ-opiate agonist EMD 61753 and analogues: opioid activity versus peripheral selectivity. Drugs Exptl. Clin. Res., 21, 171-174.
10. Gros, P., Croop, J. & Housman, D. (1986). Mammalian multidrug resistance gene: complete cDNA sequence indicates strong homology to bacterial transport proteins. Cell, 47, 371-380.
11. Huwyler, J., Drewe, J., Klusemann, C. & Fricker, G. (1996). Evidence for P-glycoprotein-modulated penetration of morphine-6-glucuronide into brain capillary endothelium. Br. J. Pharmacol., 118, 1879-1885.
12. Juliano, R.L. & Ling, V. (1976). A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. Biochim. Biophys. Acta, 445, 152-162.
13. Kim, R.B., Fromm, M.F., Wandel, C., Leake, B., Wood, A.J.J. & Roden, D.M. (1998). The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors. J. Clin. Invest., 101, 289-294.
14. Mayer, U., Wagenaar, E., Beijnen, J.H., Smith, J.W., Meijer, D.K.F., Van Asperen, J., Borst, P. & Schinkel, A.H. (1996). Substantial excretion of digoxin via the intestinal mucosa and prevention of long-term digoxin accumulation in the brain by the mdr1a P-glycoprotein. Br. J. Pharmacol., 119, 1038-1044.
15. Mayer, U., Wagenaar, E., Dorobek, B., Beijnen, J.H., Borst, P. & Schinkel, A.H. (1997). Full blockade of intestinal P-glycoprotein and extensive inhibition of blood-brain barrier P-glycoprotein by oral treatment of mice with PSC833. J. Clin. Invest., 100, 2430-2436.
16. Schinkel, A.H. (1997). The physiological function of drug-transporting P-glycoproteins. Semin. Cancer Biol., 8, 161-170.
17. Schinkel, A.H., Mayer, U., Wagenaar, E., Mol, C.A.A.M., Van Deemter, L., Smit, J.J.M., Van Der Valk, M.A., Voordouw, A.C., Spits, H., Van Tellingen, O., Zijlmans, J.M.J.M., Fibbe, W.E & Borst, P. (1997). Normal viability and altered phamacokinetics in mice lacking mdr1-type (drug-transporting) P-glycoproteins. Proc. Natl. Acad. Sci. U.S.A., 94, 4028-4033.
18. Schinkel, A.H., Smit, J.J.M., Van Tellingen, O., Beijnen, J.H., Wagenaar, E., Van Deemter, L., Mol, C.A.A.M., Van Der Valk, M.A., Robanus-Maandag, E.C., Te Riele, H.P.J., Berns, A.J.M. & Borst, P. (1994). Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs. Cell, 77, 491-502.
19. Schinkel, A.H., Wagenaar, E., Mol, C.A.A.M. & Van Deemter, L. (1996). P-glycoprotein in the blood-brain barrier of mice influences the brain penetration and pharmacological activity of many drugs. J. Clin. Invest., 97, 2517-2524.
20. Schinkel, A.H., Wagenaar, E., Van Deemter, L., Mol, C.A.A.M. & Borst, P. (1995). Absence of the mdr1a P-glycoprotein in mice affects tissue distribution and pharmacokinetics of Dexamethasone, Digoxin and Cyclosporin A. J. Clin. Invest., 96, 1698-1705.
21. Smit, J.W., Schinkel, A.H., Müller, M., Weert, B. & Meijer, D.K.F. (1998a). Contribution of the murine mdr1a P-glycoprotein to hepatobiliary and intestinal elimination of cationic drugs as measured in mice with an mdr1a gene disruption. Hepatology, 27, 1056-1063.
22. Smit, J.W., Weert, B., Schinkel, A.H. & Meijer, D.K.F (1998b). Heterologous expression of various P-glycoproteins in polarized epithelial cells induces directional transport of small (type 1) and bulky (type 2) cationic drugs. J. Pharmacol. Exp. Ther., 286, 321-327.
23. Sparreboom, A., Van Asperen, J., Mayer, U., Schinkel, A.M., Smit, J.W., Meijer, D.K.F., Borst, P., Nooijen, W.J., Beijnen, J. & Van Tellingen, O. (1997). Limited oral bioavailability and active epithelial excretion of paclitaxel (taxol) caused by P-glycoprotein in the intestine. Proc. Natl. Acad. Sci. U.S.A., 94, 2031-2035.
24. Stein, C. & Schäfer, M. (1997). Peripheral opioid analgesia: basic and clinical aspects. Semin. Anesth., 16, 112-116.
25. Van Asperen, J., Mayer, U., Van Tellingen, O. & Beijnen, J.H. (1997a). The functional role of P-glycoprotein in the blood-brain barrier. J. Pharm. Sci., 86, 881-884.
26. Van Asperen, J., Van Tellingen, O., Sparreboom, A., Schinkel, A.H., Borst, P., Nooijen, W.J. & Beijnen, J.H. (1997b). Enhanced oral bioavailability of paclitaxel in mice treated with the P-glycoprotein blocker SDZ PSC 833. Br. J. Cancer, 76, 1181-1183.
27. Wacher, V.J., Wu, C.-Y. & Benet, L.Z. (1995). Overlapping substrate specificities and tissue distribution of cytochrome P450 3A and P-glycoprotein: implications for drug delivery and activity in cancer chemotherapy. Mol. Carcinogen., 13, 129-134.